The FDA has announced two additional drug-related drug recalls with a carcinogenic impurity.
Legacy Pharmaceutical Packaging, LLC Announced Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to Detection of Leakage Levels N-nitroso-N-methyl-4-amino-butyric acid (NMBA) drug contaminant (API) found.
Recall is the latest in an ongoing study of a class of drugs known as angiotensin receptor blockers or ARBs containing either valsartan, losartan or irbesartan and used in patients with hypertension and other conditions.
Starting in July, a number of different ARB blood pressure and heart failure medicines from various companies around the world have been recalled by the United States because they contain similar contaminants that may or may be suspected of causing potential carcinogens.
Here is the full list of recalled medicines.